Hetero-dimeric multi-specific antibody format
The invention relates to a novel hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively.
1. A hetero-dimeric protein comprising a first and a second single-chain protein,
wherein said first single-chain protein comprises a first amino acid sequence consisting of (from the N- to the C-terminus):
(ia) a first VL domain;
(iia) a first polypeptide linker and
(iiia) a second VL domain, and
wherein said second single-chain protein comprises a second amino acid sequence consisting of (from the N- to the C-terminus):
(ib) a first VH domain;
(iib) a second polypeptide linker and
(iiib) a second VH domain, and
wherein said first VL domain forms a first cognate pair of variable domains with specificity to a first target antigen with either said first or said second VH domain, and said second VL domain forms a second cognate pair of variable domains with specificity to a second target antigen with the other of said VH domains, and wherein at least one of said first or said second single-chain protein further comprises:
(iv) a third functional domain that is fused via a third polypeptide linker to said first or said second amino acid sequence;
(v) at least one additional domain as a fourth functional domain that is fused via a fourth polypeptide linker to said first or said second amino acid sequence, so that said hetero-dimeric protein is at least tetraspecific; and
wherein said hetero-dimeric protein does not comprise (i) a cognate pair of a first and a second immunoglobulin constant domain, wherein said first immunoglobulin constant domain is comprised in said first single-chain protein and wherein said second immunoglobulin constant domain is comprised in said second single-chain protein, and wherein said hetero-dimeric protein does not comprise (ii) any further pair of heteroassociation domains, in which one heteroassociation domain of said further pair of heteroassociation domains is located on the first single-chain protein, and the other heteroassociation domain is located on the second single-chain protein, other than said first and second cognate pairs of variable domains,
wherein at least one of said VL and/or VH domains comprises human framework regions, wherein at least one of said VL domains comprises (i) human Vκ framework regions I to III; (ii) CDR domains CDR1, CDR2 and CDR3; and (iii) a framework region IV, which is a human Vλ germ line sequence for framework region IV.
2. The hetero-dimeric protein of claim 1 , further comprising
(vi) a fifth functional domain that is fused via a fifth polypeptide linker to said first and said second amino acid sequence; or
(vi) a fifth and a sixth functional domain that are fused via a fifth and a sixth polypeptide linker, respectively, to said first and said second amino acid sequence.
3. The hetero-dimeric protein of claim 1 , wherein said first polypeptide linker consists of from 5 to 20 amino acid residues.
4. The hetero-dimeric protein of claim 1 , wherein (a) said first VL domain (ia) and said first VH domain (ib) form a first cognate pair of variable domains with specificity to a first target antigen, and said second VL domain (iia) and said second VH domain (iib) form a second cognate pair of variable domains with specificity to a second target antigen; or (b) said first VL domain (ia) and said second VH domain (iib) form a first cognate pair of variable domains with specificity to a first target antigen, and said second VL domain (iia) and said first VH domain (ib) form a second cognate pair of variable domains with specificity to a second target antigen.
5. The hetero-dimeric protein of claim 1 , wherein said third and/or fourth functional domains are independently selected from the list of: binding domains, toxins, enzymes, hormones, signaling proteins, and albumins; particularly wherein said third and/or fourth functional domains are independently selected from binding domains; particularly wherein said binding domains are independently selected from the list of: antibody-based binding domains, particularly scFv fragments, Fab fragments and single antibody variable domains, and binding domains based on alternative scaffolds, particularly ankyrin-based domains, fynomers, avimers, anticalins and binding sites being built into constant regions of antibodies.
6. The hetero-dimeric protein of claim 1 , wherein at least one of said VL and/or VH domains comprises CDR regions derived from a parental rabbit antibody.
7. The hetero-dimeric protein of claim 1 , wherein the cognate pair of one of said first and said second VL and VH domains is specific for an antigen selected from the list of: a cancer target; and a target present on immune effector cells.
8. A nucleic acid sequence or two nucleic acid sequences encoding the first and the second single-chain proteins of the hetero-dimeric protein of claim 1 .
9. A vector or two vectors comprising the nucleic acid sequence or the two nucleic acid sequences of claim 8 .
10. A host cell or host cells comprising the vector or the two vectors of claim 9 .
11. A method for producing the hetero-dimeric protein of claim 1 , or the first and the second single-chain proteins of said hetero-dimeric protein, comprising (i) providing a nucleic acid sequence or two nucleic acid sequences encoding the first and the second single-chain proteins of the hetero-dimeric protein of claim 1 , or a vector or two vectors comprising said nucleic acid sequence or nucleic acid sequences, expressing said nucleic acid sequence or nucleic acid sequences, or said vector or vectors, and collecting said hetero-dimeric protein, or (ii) providing a host cell or host cells comprising said vector or vectors, culturing said host cell or said host cells; and collecting said first and second single-chain proteins, or said hetero-dimeric protein, from the cell culture.
12. A pharmaceutical composition comprising the hetero-dimeric protein of claim 1 and a pharmaceutically acceptable carrier.
13. The hetero-dimeric protein of claim 1 for use in the treatment of a disease, wherein at least one of said cognate pairs of VL and VH domains, or of said third or fourth functional domain is able to specifically interact with a target of therapeutic relevance in the disease.
14. The hetero-dimeric protein of claim 7 , wherein said antigen is CD3.
15. The hetero-dimeric protein of claim 1 for use in the treatment of a human disease, wherein at least one of said cognate pairs of VL and VH domains, or of said third or fourth functional domain is able to specifically interact with a target of therapeutic relevance in the disease.
16. The hetero-dimeric protein of claim 1 for use in the treatment of a human disease selected from cancer, an inflammatory and an autoimmune disease, wherein at least one of said cognate pairs of VL and VH domains, or of said third or fourth functional domain is able to specifically interact with a target of therapeutic relevance in the disease.
17. The hetero-dimeric protein of claim 1 , wherein said first polypeptide linker consists of from 6 to 15 amino acid residues.